tetano
Editor, Senior Moderator
Cureus
. 2021 Nov 20;13(11):e19761.
doi: 10.7759/cureus.19761. eCollection 2021 Nov.
The Emergence of Cryptococcemia in COVID-19 Infection: A Case Report
Yerandy Gil[SUP] 1 [/SUP], Yusleidi D Gil[SUP] 1 [/SUP], Theodore Markou[SUP] 2 [/SUP]
Affiliations
Abstract
Cryptococcus neoformans is a fungus that can cause pulmonary, central nervous system, and dermatological infections, especially in an immunocompromised patient. This is a case report of a patient, who was presumptively immunocompetent that developed isolated cryptococcemia while being treated for coronavirus disease 19 (COVID-19) infection. We report a case of a 59-year-old Hispanic man with a past medical history of hypertension, well-controlled diabetes mellitus, and class I obesity who was admitted for severe acute respiratory distress syndrome coronavirus 2 (SARS-COV-2) and subsequently was diagnosed with cryptococcal fungemia. The patient received 21 days of dexamethasone and during this period, blood and fungal cultures grew C. neoformans. The patient was alert and oriented, did not have focal neurological deficits or meningeal irritation signs; nonetheless, a lumbar puncture was attempted, but not successful. He was treated with intravenous amphotericin B for two weeks, followed by oral fluconazole for six weeks. Repeat blood cultures demonstrated clearance and he improved clinically. In conclusion, this case report describes the possibility of an association between the use of dexamethasone in COVID-19 patients and the development of cryptococcal fungemia. In the review of literature, rare case reports worldwide have discussed this topic. This is clinically challenging as the emergence of opportunistic infections in these debilitated hosts can be detrimental. Maintaining a high clinical suspicion for this opportunistic infection while treating COVID-19 patients is necessary to prevent further mortality associated with this pandemic.
Keywords: covid-19; cryptococcus neoformans (c. neoformans); dexamethasone; immunocompetent; opportunistic infection.
. 2021 Nov 20;13(11):e19761.
doi: 10.7759/cureus.19761. eCollection 2021 Nov.
The Emergence of Cryptococcemia in COVID-19 Infection: A Case Report
Yerandy Gil[SUP] 1 [/SUP], Yusleidi D Gil[SUP] 1 [/SUP], Theodore Markou[SUP] 2 [/SUP]
Affiliations
- PMID: 34938636
- PMCID: PMC8685839
- DOI: 10.7759/cureus.19761
Abstract
Cryptococcus neoformans is a fungus that can cause pulmonary, central nervous system, and dermatological infections, especially in an immunocompromised patient. This is a case report of a patient, who was presumptively immunocompetent that developed isolated cryptococcemia while being treated for coronavirus disease 19 (COVID-19) infection. We report a case of a 59-year-old Hispanic man with a past medical history of hypertension, well-controlled diabetes mellitus, and class I obesity who was admitted for severe acute respiratory distress syndrome coronavirus 2 (SARS-COV-2) and subsequently was diagnosed with cryptococcal fungemia. The patient received 21 days of dexamethasone and during this period, blood and fungal cultures grew C. neoformans. The patient was alert and oriented, did not have focal neurological deficits or meningeal irritation signs; nonetheless, a lumbar puncture was attempted, but not successful. He was treated with intravenous amphotericin B for two weeks, followed by oral fluconazole for six weeks. Repeat blood cultures demonstrated clearance and he improved clinically. In conclusion, this case report describes the possibility of an association between the use of dexamethasone in COVID-19 patients and the development of cryptococcal fungemia. In the review of literature, rare case reports worldwide have discussed this topic. This is clinically challenging as the emergence of opportunistic infections in these debilitated hosts can be detrimental. Maintaining a high clinical suspicion for this opportunistic infection while treating COVID-19 patients is necessary to prevent further mortality associated with this pandemic.
Keywords: covid-19; cryptococcus neoformans (c. neoformans); dexamethasone; immunocompetent; opportunistic infection.